Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate Publication Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate See how QSP modeling guided the design of a reversible antibody switch that unmasks IL-12…Certara2026 年 7 月 24 日
Assessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualification Poster Assessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualification See how Simcyp Simulator V20–V24 DDI predictions were shown equivalent to the EMA-qualified V19 using…Certara2026 年 7 月 24 日
A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans Poster A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans See how quantitative pharmacology and PBPK modeling supported first in human dose selection for a…Certara2026 年 7 月 20 日
Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data Publication Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data QSP modeling reveals patient-specific factors driving CAR T-cell response and relapse in multiple myeloma, with…Certara2026 年 7 月 20 日
From Dosimetry to Dose Decisions How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development Webinar From Dosimetry to Dose Decisions How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development Hunter Stephens, PhD2026 年 7 月 17 日
Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis Publication Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis Explore how model-based meta-analysis supports dose optimization, trial design, and regulatory decisions, plus emerging roles…Certara2026 年 7 月 16 日
When to conduct hepatic impairment studies and when modeling may be enough Blog When to conduct hepatic impairment studies and when modeling may be enough How to decide if a hepatic impairment study is required, choose the right study design,…Certara2026 年 7 月 13 日
ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop Conference ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop Certara2026 年 7 月 9 日
Integrated mechanistic modeling approaches in oncology drug development Webinar Integrated mechanistic modeling approaches in oncology drug development Certara2026 年 7 月 8 日